- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Mankind Pharma Moves Delhi HC Against Kind Marks, Court Restrains Florakind, Coskind, 4 Others

Mankind Pharma submitted that it owned the registered marks “Mankind”, “Kind” and several related marks, including “Flokind” and “Coxkind”, and had developed substantial goodwill and reputation through their extensive use. It alleged that the defendant had deliberately adopted multiple marks containing “Kind” to benefit from this reputation.
The company further argued that using deceptively similar marks for identical or similar pharmaceutical products could confuse consumers and cause prejudice. It sought interim protection under Order 39 Rules 1 and 2 read with Section 151 CPC.
The supplied report does not record any submissions made by the defendant. The injunction was granted ex parte.
Examining the request for interim relief, the Court noted Mankind Pharma’s registrations for “Mankind”, “Kind” and related marks, including “Flokind”, “Coxkind”, “Rabekind” and “Pantakind”, together with the goodwill generated through prolonged commercial use. It prima facie considered the defendant’s marks deceptively similar because they incorporated the “Kind” element and closely resembled the company’s marks. Their use for identical or similar pharmaceutical goods, involving common consumers and trade channels, created a likelihood of confusion.
Referring to Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73, the Court emphasised that similarity between medicinal marks requires stricter scrutiny because of the possible consequences for public health. It also prima facie found that the defendant’s adoption of the marks could exploit Mankind Pharma’s goodwill and lead consumers to believe that its products were associated with the company, supporting the claim of passing off. The Court concluded that a prima facie case existed, the balance of convenience favoured Mankind Pharma, and withholding protection could cause irreparable injury.
Until the next hearing, the defendant and anyone acting on its behalf were restrained from manufacturing, selling, offering for sale, advertising, marketing or otherwise dealing in the impugned goods under “Florakind”, “Coskind”, “Etorikind”, “Pandokind”, “Rabelkind”, “M-Predkind”, or any identical or deceptively similar “Kind”-formative trade mark or trade name, SCC Online reported.
Mankind Pharma was also directed to comply with Order 39 Rule 3 CPC within two weeks from execution of the local commission. The relief is an ex parte ad interim injunction, reports SCC Online.
Mpharm (Pharmacology)
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

